Metachronous Immune-Related Adverse Events Involving Type 1 Diabetes and Isolated ACTH Deficiency Associated with Pembrolizumab Monotherapy for Metastatic Head and Neck Cancer: A Case Report

Abstract

1. Abstract
1.1. Background: The application of Immune Checkpoint Inhibitors (ICIs) among patients with head and neck cancer nivolumab was approved in Japan in March 2017, while the application of pembrolizumab among patients with recurrent or metastatic head and neck cancer was approved in December 2019.